Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Biogen lowers full-year earnings guidance, 3Q revenue beats expectations
01:24pm, Wednesday, 08'th Nov 2023
Biogen Inc (NASDAQ:BIIB) revised its full-year earnings guidance downward due to acquisition-related costs following the company's $7.3 billion bid for Reata Pharmaceuticals in July. The firm said it
Biogen Inc. (BIIB) Q3 2023 Earnings Call Transcript
01:03pm, Wednesday, 08'th Nov 2023
Biogen Inc. (NASDAQ:BIIB ) Q3 2023 Results Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Chuck Triano - Head of Investor Relations Christopher Viehbacher - President and Ch
Biogen (BIIB) Beats on Q3 Earnings & Sales, Cuts EPS View
12:01pm, Wednesday, 08'th Nov 2023
Biogen (BIIB) beats third-quarter estimates for earnings and sales. It lowers its 2023 EPS guidance range to include the impact of dilution from the Reata acquisition.
Biogen quarterly results top estimates despite complex launch of new Alzheimer's treatment
07:10am, Wednesday, 08'th Nov 2023
Biogen Inc. BIIB, -1.21% on Wednesday reported third quarter results that topped analyst estimates, even as it navigates a complex launch of its new Alzheimer's treatment Leqembi.
Biogen cuts annual profit forecast on persistent higher costs
07:03am, Wednesday, 08'th Nov 2023
Biogen cut its annual profit forecast below Wall Street expectations on Wednesday, on rising costs related to the recent acquisition of rare disease drugmaker Reata Pharmaceuticals and the launch of i
Biogen Earnings Are Soon. What to Watch.
04:30pm, Tuesday, 07'th Nov 2023
Wall Street will likely be more interested in updates on future developments, rather than the latest quarter's numbers.
Why Biogen (BIIB) Might Surprise This Earnings Season
09:46am, Tuesday, 07'th Nov 2023
Biogen (BIIB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Countdown to Biogen Inc. (BIIB) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
01:32pm, Monday, 06'th Nov 2023
Evaluate the expected performance of Biogen Inc. (BIIB) for the quarter ended September 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key me
Biogen (BIIB) to Report Q3 Earnings: Will It Beat Estimates?
09:47am, Monday, 06'th Nov 2023
Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:18am, Wednesday, 01'st Nov 2023
Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen Inc. (BIIB) Rises But Trails Market: What Investors Should Know
06:48pm, Monday, 30'th Oct 2023
The latest trading day saw Biogen Inc. (BIIB) settling at $237.30, representing a +1.19% change from its previous close.
Biogen and Eisai's Revised Alzheimer's Drug Works, but Safety Questions Linger
10:35am, Thursday, 26'th Oct 2023
Wall Street analysts say Biogen and Eisai could secure Food and Drug Administration approval for their injected Alzheimer's drug.
Biogen and Eisai release new Alzheimer's drug data that may support wider uptake
05:28pm, Wednesday, 25'th Oct 2023
Biogen Inc. and Eisai Co. late Wednesday released new data on their Alzheimer's treatment Leqembi that may ultimately help bolster uptake of the drug.
Here's Why Biogen Inc. (BIIB) Fell More Than Broader Market
07:33pm, Monday, 23'rd Oct 2023
The latest trading day saw Biogen Inc. (BIIB) settling at $253.39, representing a -1.58% change from its previous close.
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug
03:28pm, Monday, 23'rd Oct 2023
Swiss pharmaceutical company Roche has settled a patent lawsuit against U.S. biotech firm Biogen over its biosimilar version of Roche's blockbuster rheumatoid arthritis drug Actemra, according to a fi
